IL222030A - Non-Nuclusid Reverse Transcriptase Inhibitors - Google Patents

Non-Nuclusid Reverse Transcriptase Inhibitors

Info

Publication number
IL222030A
IL222030A IL222030A IL22203012A IL222030A IL 222030 A IL222030 A IL 222030A IL 222030 A IL222030 A IL 222030A IL 22203012 A IL22203012 A IL 22203012A IL 222030 A IL222030 A IL 222030A
Authority
IL
Israel
Prior art keywords
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
nucleoside
inhibitors
Prior art date
Application number
IL222030A
Other languages
English (en)
Hebrew (he)
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL222030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of IL222030A publication Critical patent/IL222030A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL222030A 2010-03-30 2012-09-20 Non-Nuclusid Reverse Transcriptase Inhibitors IL222030A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (en) 2010-03-30 2011-03-28 Non-nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
IL222030A true IL222030A (en) 2014-07-31

Family

ID=44710363

Family Applications (2)

Application Number Title Priority Date Filing Date
IL222030A IL222030A (en) 2010-03-30 2012-09-20 Non-Nuclusid Reverse Transcriptase Inhibitors
IL233334A IL233334A (en) 2010-03-30 2014-06-23 Compounds 3– (optionally converted aromatic hydrochloride and elliptic hydrocarbyl) –1 - [(5-oxo-5,4-dihydro-1h – 4,2,1-triazole-3-ram) methyl] -pyridine-2– (1h) - On, the pharmacy composition containing and using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL233334A IL233334A (en) 2010-03-30 2014-06-23 Compounds 3– (optionally converted aromatic hydrochloride and elliptic hydrocarbyl) –1 - [(5-oxo-5,4-dihydro-1h – 4,2,1-triazole-3-ram) methyl] -pyridine-2– (1h) - On, the pharmacy composition containing and using them

Country Status (44)

Country Link
US (2) US8486975B2 (enExample)
EP (2) EP2924034B1 (enExample)
JP (2) JP5281718B2 (enExample)
KR (1) KR101421861B1 (enExample)
CN (1) CN102971308B (enExample)
AR (1) AR080859A1 (enExample)
AU (1) AU2011235568B2 (enExample)
BR (1) BR112012024691B1 (enExample)
CA (1) CA2794377C (enExample)
CL (1) CL2012002744A1 (enExample)
CO (1) CO6630126A2 (enExample)
CR (1) CR20120503A (enExample)
CY (3) CY1118774T1 (enExample)
DK (2) DK2924034T3 (enExample)
DO (1) DOP2012000256A (enExample)
EA (1) EA024804B1 (enExample)
EC (1) ECSP12012201A (enExample)
ES (2) ES2609636T3 (enExample)
FI (1) FIC20190021I1 (enExample)
GE (1) GEP20156368B (enExample)
HN (1) HN2012002039A (enExample)
HR (2) HRP20150427T1 (enExample)
HU (4) HUE025336T2 (enExample)
IL (2) IL222030A (enExample)
LT (3) LT2924034T (enExample)
LU (2) LUC00114I2 (enExample)
MA (1) MA34170B1 (enExample)
ME (2) ME02570B (enExample)
MX (1) MX2012011379A (enExample)
MY (1) MY163979A (enExample)
NI (1) NI201200146A (enExample)
NL (1) NL300980I2 (enExample)
NO (2) NO2019019I1 (enExample)
NZ (1) NZ602670A (enExample)
PE (1) PE20130158A1 (enExample)
PH (1) PH12012501923A1 (enExample)
PL (2) PL2924034T3 (enExample)
PT (2) PT2924034T (enExample)
RS (2) RS55505B1 (enExample)
SG (1) SG184347A1 (enExample)
SI (2) SI2924034T1 (enExample)
TN (1) TN2012000455A1 (enExample)
TW (1) TWI458719B (enExample)
WO (1) WO2011120133A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
EP2900240B1 (en) * 2012-09-26 2020-01-08 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104994855B (zh) * 2012-12-05 2018-06-05 默沙东公司 制备逆转录酶抑制剂的方法
EP3071037A4 (en) * 2013-11-22 2017-08-02 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
KR101803671B1 (ko) * 2013-12-04 2017-11-30 머크 샤프 앤드 돔 코포레이션 역전사효소 억제제의 제조 방법
SI3125894T1 (sl) 2014-04-01 2020-12-31 Merck Sharp & Dohme Corp. Predzdravila inhibitorjev reverzne transkriptaze HIV
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
RU2736941C2 (ru) 2015-12-02 2020-11-23 Мерк Шарп энд Доум Корп. Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
RU2019136678A (ru) 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2020018352A1 (en) 2018-07-17 2020-01-23 Merck Sharp & Dohme Corp. Hiv drug combination for increasing barrier against resistance
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法
CN116903590A (zh) * 2023-06-06 2023-10-20 延边大学 一种含杂环结构的吡啶酮类化合物及其制备方法和用途
CN120157613A (zh) * 2023-12-15 2025-06-17 山东诚创蓝海医药科技有限公司 多拉韦林中间体及其应用和合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
AU2005235692B2 (en) 2004-04-23 2011-11-10 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Hiv−1逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CN101952274A (zh) 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
MX2012011379A (es) * 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.

Also Published As

Publication number Publication date
EA024804B1 (ru) 2016-10-31
LUC00113I9 (enExample) 2024-06-07
EP2552902A1 (en) 2013-02-06
AR080859A1 (es) 2012-05-16
CY2019026I1 (el) 2020-05-29
CR20120503A (es) 2013-01-09
KR20120128703A (ko) 2012-11-27
NL300980I2 (nl) 2021-06-17
CY2019025I2 (el) 2019-11-27
US20110245296A1 (en) 2011-10-06
HUS1900022I1 (hu) 2019-05-28
KR101421861B1 (ko) 2014-07-22
CY2019025I1 (el) 2019-11-27
EA201290976A1 (ru) 2013-03-29
IL233334A (en) 2015-09-24
CO6630126A2 (es) 2013-03-01
EP2552902B1 (en) 2015-03-11
TN2012000455A1 (en) 2014-01-30
EP2924034A1 (en) 2015-09-30
NO2019018I1 (no) 2019-04-24
BR112012024691B1 (pt) 2020-11-17
GEP20156368B (en) 2015-09-25
PL2552902T3 (pl) 2015-10-30
PT2924034T (pt) 2017-01-06
LT2924034T (lt) 2016-12-27
PT2552902E (pt) 2015-06-02
HK1175471A1 (en) 2013-07-05
JP2013209405A (ja) 2013-10-10
DK2924034T3 (en) 2017-02-06
ECSP12012201A (es) 2012-10-30
HRP20161680T1 (hr) 2017-01-27
HN2012002039A (es) 2015-08-24
SI2924034T1 (sl) 2017-05-31
LTC2552902I2 (lt) 2019-12-10
SI2552902T1 (sl) 2015-10-30
CN102971308B (zh) 2015-02-04
MX2012011379A (es) 2012-11-30
AU2011235568A1 (en) 2012-11-01
SG184347A1 (en) 2012-11-29
NO2019019I1 (no) 2019-04-24
JP2013510800A (ja) 2013-03-28
HUE025336T2 (en) 2016-03-29
AU2011235568B2 (en) 2013-09-12
ES2536295T3 (es) 2015-05-22
MY163979A (en) 2017-11-15
CN102971308A (zh) 2013-03-13
LTC2924034I2 (lt) 2020-10-12
TWI458719B (zh) 2014-11-01
TW201139409A (en) 2011-11-16
PH12012501923A1 (en) 2013-02-04
BR112012024691A2 (pt) 2019-07-02
CA2794377A1 (en) 2011-10-06
HUS1900021I1 (hu) 2019-05-28
LTPA2019506I1 (lt) 2019-04-25
EP2924034B1 (en) 2016-11-02
HUE031785T2 (en) 2017-08-28
HK1209121A1 (en) 2016-03-24
CA2794377C (en) 2015-06-16
PL2924034T3 (pl) 2017-07-31
LTPA2019507I1 (lt) 2019-04-25
US8486975B2 (en) 2013-07-16
JP5886790B2 (ja) 2016-03-16
NL300980I1 (nl) 2019-04-24
ME02181B (me) 2015-10-20
HRP20150427T1 (hr) 2015-07-03
RS55505B1 (sr) 2017-05-31
ES2609636T3 (es) 2017-04-21
CY1118774T1 (el) 2017-07-12
LUC00114I1 (enExample) 2019-04-17
EP2552902A4 (en) 2013-09-04
ME02570B (me) 2017-06-20
DOP2012000256A (es) 2012-12-15
NZ602670A (en) 2014-09-26
FIC20190021I1 (fi) 2019-04-17
LUC00113I2 (enExample) 2024-05-22
LUC00114I2 (enExample) 2020-07-10
CY2019026I2 (el) 2020-05-29
PE20130158A1 (es) 2013-02-28
JP5281718B2 (ja) 2013-09-04
WO2011120133A1 (en) 2011-10-06
IL233334A0 (en) 2014-09-01
CL2012002744A1 (es) 2012-12-14
DK2552902T3 (en) 2015-06-15
MA34170B1 (fr) 2013-04-03
NI201200146A (es) 2013-03-18
RS54017B1 (sr) 2015-10-30
US20130296382A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
LTC2552902I2 (lt) Nenukleozidinės reversinės transkriptazės inhibitoriai
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2739221A4 (en) SURGICAL ANCHOR
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
IL230917A (en) 1dyrk inhibitors and their uses
SI2872491T1 (sl) Inhibitorji receptorja fibroblastnega rastnega faktorja
GB201002959D0 (en) Tissue expander
IL205386A0 (en) Non - nucleoside reverse transcriptase inhibitors
GB201009731D0 (en) Kinase inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
PL2533962T3 (pl) Kołek rozporowy
ZA201206456B (en) Uses of dgati inhibitors
GB201009853D0 (en) HSP90 inhibitors
LT2600723T (lt) Maisto kepimo pagalbinė priemonė
IL202143A0 (en) Non-nucleoside reverse transcriptase inhibitors
IL200886A0 (en) Non-nucleoside reverse transcriptase inhibitors
TWM388314U (en) Expander
GB201018597D0 (en) Inhibitors
GB201003502D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201120474D0 (en) Inhibitors
GB201012471D0 (en) Turbomachine
GB201012475D0 (en) Turbomachine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXTF Application for patent extension filed

Filing date: 20200729

KB Patent renewed